LLY as reported
Lilly (Eli) reported $79.7B of revenue over the trailing twelve months, +50% on the year before. 11 reported series are charted on this page, each one as filed.
$79.7B
Revenue, trailing twelve months · to Q2 2026 · +50% against the twelve months before
- Net Income
- $26.7B
Net Income · +94% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $18.2B
Free Cash Flow · +272% year on year · trailing twelve months to Q2 2026
- EPS
- $29.80
EPS · +95% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $79.7B | +50% | Q2 2026 |
| Net Income | $26.7B | +94% | Q2 2026 |
| EPS | $29.80 | +95% | Q2 2026 |
| Gross Margin | 83% | n/a | Q2 2026 |
| Op Margin | 26% | n/a | Q4 2019 · 26 quarters behind |
| Net Margin | 34% | n/a | Q2 2026 |
| ROE | 79% | n/a | Q2 2026 |
| ROA | 19% | n/a | Q2 2026 |
| ROIC | 27% | n/a | Q4 2019 · 26 quarters behind |
| Free Cash Flow | $18.2B | +272% | Q2 2026 |
| P/E | 39.9 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Lilly (Eli) (LLY) - Revenue & ProfitRevenue & ProfitLilly (Eli) (LLY)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - General
Ranks #1 of 16 by Smart Score